phenylketonuric patient
Recently Published Documents


TOTAL DOCUMENTS

7
(FIVE YEARS 0)

H-INDEX

2
(FIVE YEARS 0)

2020 ◽  
Vol 44 (11) ◽  
Author(s):  
Shruti Pandey ◽  
Aleena Sunny ◽  
Karadka Govindaraju ◽  
Ravindra P. Singh

1997 ◽  
Vol 20 (4) ◽  
pp. 603-604 ◽  
Author(s):  
T. T. Aung ◽  
A. Klied ◽  
J. McGinn ◽  
T. McGinn

1986 ◽  
Vol 9 (S2) ◽  
pp. 215-217
Author(s):  
A. Rottoli ◽  
E. Riva ◽  
G. Zecchini ◽  
F. Magno ◽  
A. Fiocchi ◽  
...  

1978 ◽  
Vol 92 (4) ◽  
pp. 681-682 ◽  
Author(s):  
F. Ziyai ◽  
P.W.K. Wong ◽  
P. Justice ◽  
K. Michals

PEDIATRICS ◽  
1967 ◽  
Vol 40 (1) ◽  
pp. 142-142
Author(s):  
JOHN H. MENXES

Dr. Dancis's letter underlines the complexities encountered in studying the various metabolic alterations resulting from a derangement of the internal environment as seen in phenylketonuria. It is a clinical fact that phenylketonuric individuals have diluted hair and iris pigmentation and that this defect is reversible by restriction in phenylalanine intake or supplementation of a normal diet by tyrosine. The inhibition by phenylalanine of tyrosinase derived from embryonic skin (Saunders, et al.), mushrooms (Dancis and Balis), or mammalian melanoma (Miyamoto and Fitzpatrick) suggests but one of several possible sites at which melanin formation may be inhibited in the phenylketonuric patient.


Sign in / Sign up

Export Citation Format

Share Document